NASDAQ:GWPH GW Pharmaceuticals (GWPH) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free GWPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$218.96▼$218.9650-Day Range$216.90▼$219.2852-Week Range$87.07▼$219.57VolumeN/AAverage Volume899,771 shsMarket Capitalization$6.86 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GW Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About GW Pharmaceuticals Stock (NASDAQ:GWPH)GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him GWPH Stock News HeadlinesOctober 14, 2023 | powermag.comMelaka: Malaysia’s 2.2-GW Cutting-Edge Combined Cycle Gas Power PlantSeptember 28, 2023 | uk.investing.comGWPRF Historical DataApril 25, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.August 17, 2023 | usnews.comGeorge Washington UniversityMarch 9, 2023 | powermag.comChina Approves 106 GW of New Coal-Fired CapacityFebruary 19, 2023 | thestreet.comWhy Nasdaq-Traded Marijuana Stocks Remain UndervaluedSeptember 25, 2022 | investing.comGW Pharmaceuticals PLC (GWPRF)August 22, 2022 | benzinga.comMedical Marijuana Market Size Worth $40 Billion by 2028 at 19.2% CAGR, COVID-19 Impact and Global Analysis by The Insight PartnersApril 25, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.June 15, 2022 | thestreet.comWhy Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016March 3, 2022 | msn.comCourt Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW PharmaFebruary 15, 2022 | marketwatch.comMedical Marijuana Market Forecast With Trends, Challenges, Growth Drivers, And Top Key PlayersJanuary 25, 2022 | thestreet.comThese 3 Marijuana-Related Stocks Are Poised for Strong GrowthJanuary 21, 2022 | finance.yahoo.comGWPH Jan 2023 195.000 putDecember 15, 2021 | msn.comStudy Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy TreatmentNovember 1, 2021 | benzinga.comAadi Bioscience Appoints Scott Giacobello as Chief Financial OfficerOctober 26, 2021 | finance.yahoo.comToday's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW PharmaceuticalsOctober 26, 2021 | finance.yahoo.comGW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?August 4, 2021 | law360.com2 Firms Seek To Lead GW Pharma Suit Over $7.2B DealAugust 4, 2021 | msn.comJazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02BSee More Headlines Receive GWPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GWPH CUSIPN/A CIK1351288 Webwww.gwpharm.com Phone44-12-2326-6800FaxN/AEmployees1,161Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,020,000.00 Net Margins-11.05% Pretax MarginN/A Return on Equity-7.46% Return on Assets-6.13% Debt Debt-to-Equity Ratio0.01 Current Ratio5.13 Quick Ratio4.31 Sales & Book Value Annual Sales$311.33 million Price / Sales22.05 Cash Flow$0.01 per share Price / Cash Flow18,588.22 Book Value$23.48 per share Price / Book9.33Miscellaneous Outstanding Shares31,349,000Free FloatN/AMarket Cap$6.86 billion OptionableOptionable Beta2.15 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Justin D. Gover (Age 50)CEO & Exec. Director Comp: $1.19MMr. Scott M. Giacobello (Age 51)Chief Financial Officer Comp: $743.33kMr. Douglas B. Snyder (Age 57)Chief Legal Officer & Sec. Comp: $787.02kDr. Volker Knappertz M.D. (Age 56)D.Sc., Chief Medical Officer Comp: $830.47kMr. Christopher John Tovey (Age 56)Chief Operating Officer Kristen CardilloVP of Corp. CommunicationMs. Tina St. LegerChief HR OfficerProf. Ben WhalleyHead of Discovery ResearchMr. Darren S. Cline (Age 57)U.S. Chief Commercial Officer More ExecutivesKey CompetitorsCytokineticsNASDAQ:CYTKJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANViking TherapeuticsNASDAQ:VKTXIntra-Cellular TherapiesNASDAQ:ITCIView All Competitors GWPH Stock Analysis - Frequently Asked Questions How were GW Pharmaceuticals' earnings last quarter? GW Pharmaceuticals plc (NASDAQ:GWPH) posted its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company had revenue of $137.10 million for the quarter, compared to the consensus estimate of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. The business's revenue for the quarter was up 50.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) EPS. What is Justin Gover's approval rating as GW Pharmaceuticals' CEO? 14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among the company's employees. What other stocks do shareholders of GW Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD). This page (NASDAQ:GWPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GW Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
